Maze Therapeutics (NASDAQ:MAZE) Shares Down 5.8% on Insider Selling

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s stock price fell 5.8% on Monday following insider selling activity. The company traded as low as $25.85 and last traded at $25.85. 203,386 shares were traded during mid-day trading, a decline of 68% from the average daily volume of 642,078 shares. The stock had previously closed at $27.44.

Specifically, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $27.58, for a total transaction of $206,850.00. Following the transaction, the insider directly owned 26,250 shares of the company’s stock, valued at approximately $723,975. The trade was a 22.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MAZE. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. BTIG Research reissued a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Maze Therapeutics currently has a consensus rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Stock Down 0.2%

The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The stock’s 50-day moving average price is $28.76 and its 200-day moving average price is $31.49. The company has a market cap of $1.47 billion, a P/E ratio of -10.53 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.76). As a group, research analysts forecast that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Institutional Investors Weigh In On Maze Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Royal Bank of Canada raised its position in shares of Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares during the period. Ameritas Investment Partners Inc. grew its position in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in Maze Therapeutics during the 4th quarter valued at $43,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Maze Therapeutics during the 2nd quarter valued at $48,000. Finally, Russell Investments Group Ltd. raised its holdings in Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after buying an additional 1,725 shares during the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.